StockData

Agenus vs Beam Therapeutics

AGEN and BEAM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AGEN and BEAM compare

Beam Therapeutics is the larger company, worth 7.6 times as much as Agenus ($2.4B against $309M).

Beam Therapeutics grew revenue faster over the last twelve months (159% versus 25.4% for Agenus).

Beam Therapeutics scores higher on the StockData Score (7 against 3 for Agenus), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAGENBEAM
Size and price
Market cap$309M$2.4B
Share price$6.87$22.83
Change, 1 year60.9%4.4%
Change, 5 years−90.2%−74.6%
Beta (5Y)2.031.99
Employees81511
StockData Score
Total score37 (better)
Valuation score11
Growth score22
Performance score02 (better)
Health score02 (better)
Dividend score00
Valuation
P/S2.3× (better)15.1×
P/B–2.2×
EV/EBITDA4.5×–
FCF yield−33.6%−15.8% (better)
Fair value–$23.90
Margin of safety–4.5%
Growth
Revenue growth (TTM)25.4%159% (better)
Revenue growth, 5Y average5.3%466% (better)
Profitability
Gross margin100%–
Operating margin38.9% (better)−242%
Net margin–−54.7%
FCF margin−77.5% (better)−239%
Return on equity–−8.1%
Financial health
Debt / equity–0.09
Net debt / EBITDA−1.05–
Interest coverage0.9×–
Current ratio0.7314.57 (better)
Altman Z-score−10.712.72 (better)
Piotroski F-score–4
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions31.7%106%
Held by insiders6.6%3.4%
Insider net buying, 12 months–−$19.7M
Superinvestors holding–1
Short interest, % of float18.1%26.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.